| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A3 - A High-throughput double cocktail approach for evaluating time-dependent inhibition of nine major human cytochrome P450 enzymes
|
Kahma, Helinä
|
|
|
35 |
1S |
p. S19
|
artikel
|
| 2 |
A9 - Aldehyde oxidase contributes to all-trans-retinoic acid biosynthesis in human liver
|
Zhong, Guo
|
|
|
35 |
1S |
p. S21
|
artikel
|
| 3 |
A8 - Apical and basolateral flow rate influence intestinal absorption in fresh intestinal tissue inside a novel intestine on a chip model
|
Amirabadi, Hossein Eslami
|
|
|
35 |
1S |
p. S20-S21
|
artikel
|
| 4 |
A10 - Characterization of differential tissue abundance of major non-cyp enzymes in human
|
Neradugomma, Naveen
|
|
|
35 |
1S |
p. S21
|
artikel
|
| 5 |
A2 - Differential regulation of aldehyde oxidase by pregnane X receptor and retinoid X receptor agonists in human cell models
|
Chen, Shiyan
|
|
|
35 |
1S |
p. S18
|
artikel
|
| 6 |
A7 - Interaction with yap is a possible underlying mechanism for car-dependent hepatocarcinogenesis
|
Shizu, Ryota
|
|
|
35 |
1S |
p. S20
|
artikel
|
| 7 |
A6 - Investigating the role of drug transporters in furosemide absorption, food-effect and elimination using a proteomics informed-mechanistic PBPK modeling approach
|
Chapa, Revathi
|
|
|
35 |
1S |
p. S20
|
artikel
|
| 8 |
A1 - Is urinary testosterone glucuronide a potential biomarker for UGT2B17 ontogeny in ages 7 to 18 years?
|
Zhang, Haeyoung
|
|
|
35 |
1S |
p. S18
|
artikel
|
| 9 |
A12 - Mechanistic kidney models for creatinine: Relevance of OCT2 transport driving force to prediction of creatinine-drug interactions
|
Scotcher, Daniel
|
|
|
35 |
1S |
p. S22
|
artikel
|
| 10 |
A11 - Optimized renal transporter quantification by using Aquaporin 1 and Aquaporin 2 as anatomical markers: Application in characterizing the ontogeny of renal transporters and its correlation with hepatic transporters in paired sample
|
Li, Cindy Yanfei
|
|
|
35 |
1S |
p. S21-S22
|
artikel
|
| 11 |
A5 - The effect of changes in pharmacokinetics of transporter substrates on PBPK modeling approaches
|
Sodhi, Jasleen
|
|
|
35 |
1S |
p. S19-S20
|
artikel
|
| 12 |
A4 - Understanding the physiological functions of the xenobiotic-sensing nuclear receptors on gut microbiome using genetically-modified mice
|
Little, Mallory
|
|
|
35 |
1S |
p. S19
|
artikel
|
| 13 |
Author Index
|
|
|
|
35 |
1S |
p. I-VII
|
artikel
|
| 14 |
Keyword Index
|
|
|
|
35 |
1S |
p. VIII
|
artikel
|
| 15 |
K1 - Model-informed precision dosing at the bedside: Challenges and opportunities
|
Lesko, Lawrence J.
|
|
|
35 |
1S |
p. S5
|
artikel
|
| 16 |
L3 - Drug metabolism, pharmacogenomics and the quest to personalize HIV treatment and prevention
|
Bumpus, Namandjé
|
|
|
35 |
1S |
p. S14
|
artikel
|
| 17 |
L2 - Evaluation of disease progression / drug effects by expanding the PK concept
|
Suzuki, Hiroshi
|
|
|
35 |
1S |
p. S10
|
artikel
|
| 18 |
L1 - How technology, big data and systems approaches are transforming 21st century healthcare
|
Hood, Leroy
|
|
|
35 |
1S |
p. S5-S6
|
artikel
|
| 19 |
P154 - Absorption, distribution, metabolism, and excretion of the novel antiepileptic drug cenobamate: mass balance following oral administration in healthy male subjects
|
Glenn, Kelli J.
|
|
|
35 |
1S |
p. S69
|
artikel
|
| 20 |
P174 - Absorption, distribution, metabolism, and excretion of tropifexor, a potent FXR agonist for the treatment of NASH, following a single oral 1 mg dose of [14C]tropifexor in healthy male subjects
|
Wang-Lakshman, Lydia
|
|
|
35 |
1S |
p. S76
|
artikel
|
| 21 |
P164 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S73
|
artikel
|
| 22 |
P28 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S30
|
artikel
|
| 23 |
P12 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S25
|
artikel
|
| 24 |
P40 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S33
|
artikel
|
| 25 |
P249 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S98
|
artikel
|
| 26 |
P181 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S77
|
artikel
|
| 27 |
P67 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S42
|
artikel
|
| 28 |
P180 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S77
|
artikel
|
| 29 |
P197 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S82
|
artikel
|
| 30 |
P173 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S76
|
artikel
|
| 31 |
P185 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S79
|
artikel
|
| 32 |
P209 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S86
|
artikel
|
| 33 |
P29 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S30
|
artikel
|
| 34 |
P222 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S90
|
artikel
|
| 35 |
P53 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S38
|
artikel
|
| 36 |
P225 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S90
|
artikel
|
| 37 |
P198 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S82
|
artikel
|
| 38 |
P4 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S24
|
artikel
|
| 39 |
P24 - Abstract withdrawn
|
|
|
|
35 |
1S |
p. S29
|
artikel
|
| 40 |
P25 - Accessing mammalian drug metabolites using PolyCYPs® enzymes
|
Shanu-Wilson, Julia
|
|
|
35 |
1S |
p. S29
|
artikel
|
| 41 |
P107 - A comparison of enteric and hepatic metabolism using in vitro enteric and hepatic experimental systems: Cryopreserved human enterocytes, metmax cryopreserved enterocytes, cryopreserved human intestinal mucosa, cryopreserved human hepatocytes, and metmax cryopreserved human hepatocytes
|
Li, Albert P.
|
|
|
35 |
1S |
p. S54-S55
|
artikel
|
| 42 |
P109 - Aconitum alkaloids from Radix Aconiti Lateralis Preparata induced liver injury in rats: Mechanistic consideration on bile acid perturbations
|
Yang, Mengbi
|
|
|
35 |
1S |
p. S55
|
artikel
|
| 43 |
P149 - ACQUIREX - A new data acquisition strategy for metabolite profiling on an orbitrap ID-X tribrid mass spectrometer
|
Comstock, Kate
|
|
|
35 |
1S |
p. S67-S68
|
artikel
|
| 44 |
P146 - A high capacity and high throughput automated method for the generation of radio-profiling data to support ADME studies
|
Barros Jr., Anthony
|
|
|
35 |
1S |
p. S67
|
artikel
|
| 45 |
P251 - AHR-mediated effect of benzo(a)pyrene and smoking on microrna expression in lung cancer
|
Gulyaeva, Lyudmila
|
|
|
35 |
1S |
p. S99
|
artikel
|
| 46 |
P220 - A mechanistic PBPK/PD modeling approach to predict the effect of CYP3A4 on the pharmacokinetics and pharmacodynamics of racemic warfarin
|
Wang, Ziteng
|
|
|
35 |
1S |
p. S89
|
artikel
|
| 47 |
P184 - An evaluation of probe substrates and inhibitors of alcohol dehydrogenase, aldehyde dehydrogenase and aldehyde oxidase enzymes for use in reaction phenotyping investigations
|
Birks, Vicky
|
|
|
35 |
1S |
p. S78-S79
|
artikel
|
| 48 |
P30 - An examination of the reversibility in the effects of high fat diet on lidocaine microsomal metabolism in rats
|
Mohammed S Al Nebaihi, Hamdah
|
|
|
35 |
1S |
p. S30
|
artikel
|
| 49 |
P47 - An integrated radiolabelled study to determine the absorption, metabolism, excretion and absolute bioavailability of pemafibrate in healthy male subjects
|
Shaw, Iain
|
|
|
35 |
1S |
p. S35
|
artikel
|
| 50 |
P159 - A novel hydrolytic activation pathway for an ester-type prodrug in human plasma: Contribution of α1-acid glycoprotein variant
|
Kono, Kenta
|
|
|
35 |
1S |
p. S71
|
artikel
|
| 51 |
P195 - A novel LC-MS/MS method for pivkaii quantification: Characterization of warfarin induced altered prothrombin des-carboxylation
|
Basit, Abdul
|
|
|
35 |
1S |
p. S82
|
artikel
|
| 52 |
P137 - A novel method for the isolation of NR8383 lysosomes and measurement of intralysosomal drug concentrations
|
Francis, Laura
|
|
|
35 |
1S |
p. S64
|
artikel
|
| 53 |
P84 - A platform for evaluating in vivo OATP1B inhibition risk in cynomolgus monkeys and translation to human
|
Tatosian, Daniel
|
|
|
35 |
1S |
p. S47-S48
|
artikel
|
| 54 |
P57 - Application of an abbreviated radiolabeled ADME study utilizing 3H-labeled test article in the transition between discovery and development
|
Kim-Kang, Heasook
|
|
|
35 |
1S |
p. S39
|
artikel
|
| 55 |
P106 - Application of cryopreserved human intestinal mucosa (CHIM) in the evaluation of regional difference in intestinal drug metabolism
|
Li, Albert P.
|
|
|
35 |
1S |
p. S54
|
artikel
|
| 56 |
P113 - Application of metmax human hepatocytes in the identification of detoxification pathways of protoxicants
|
Li, Albert P.
|
|
|
35 |
1S |
p. S56-S57
|
artikel
|
| 57 |
P90 - Application of primary human hepatocytes enriched with human plasma in CYP induction studies
|
Lu, Chuang
|
|
|
35 |
1S |
p. S49-S50
|
artikel
|
| 58 |
P182 - Approach for the investigation of the biotransformation of oligonucleotide therapeutics in biological matrices using SPE, followed by LC/UV/HRMS
|
Kim-Kang, Heasook
|
|
|
35 |
1S |
p. S77-S78
|
artikel
|
| 59 |
P213 - A priori prediction of CYP3A victim drug-drug interaction of MK-1 and diltiazem using physiologically-based pharmacokinetic modeling (PBPK): qualification using clinical data
|
Gibson, Christopher
|
|
|
35 |
1S |
p. S87
|
artikel
|
| 60 |
P26 - A rapid fluorescence based screen for CYP51 inhibition
|
Voice, Michael
|
|
|
35 |
1S |
p. S29
|
artikel
|
| 61 |
P228 - Assay calibration to refine prediction of OATP1B1/1B3 mediated drug-drug interactions (DDI) based on in vitro uptake transport assay data
|
Kovacs, Peter
|
|
|
35 |
1S |
p. S91
|
artikel
|
| 62 |
P207 - Assessing the accuracy of predicted human pharmacokinetics for candidate drugs
|
McGinnity, Dermot
|
|
|
35 |
1S |
p. S85
|
artikel
|
| 63 |
P123 - Assessing the predictive performance of in silico generated binding parameters for various natural product constituents
|
Nguyen, James
|
|
|
35 |
1S |
p. S60
|
artikel
|
| 64 |
P111 - Assessment of culture systems on performance of primary human hepatocyte in 3D spheroids
|
Dunnick, Katherine
|
|
|
35 |
1S |
p. S56
|
artikel
|
| 65 |
P157 - Assessment of de-fluorination of [18F]MEFWAY in liver fractions
|
Kim, Byoung Soo
|
|
|
35 |
1S |
p. S70-S71
|
artikel
|
| 66 |
P13 - Assessment of drug metabolizing enzyme expression after high-fat feedings, and after a switch back to a normal diet in rats
|
Mohammed S Al Nebaihi, Hamdah
|
|
|
35 |
1S |
p. S25-S26
|
artikel
|
| 67 |
P27 - Association of cytochrome P450 reactivity and repeated-dose toxicity of chemical compounds
|
Watanabe, Michiko
|
|
|
35 |
1S |
p. S29-S30
|
artikel
|
| 68 |
P68 - A systemic review of drug dispostion and drug interation data for 16 new small-molecule drugs developed and approved in China between 2007 and 2018
|
Zhu, Mingshe
|
|
|
35 |
1S |
p. S42
|
artikel
|
| 69 |
P95 - A-to-I RNA editing modulates the expression of human pregnane X receptor
|
Takemoto, Seiya
|
|
|
35 |
1S |
p. S51
|
artikel
|
| 70 |
P239 - BCRP gene deletion alters the gut microbiome in mice
|
Mukherjee, Kamalika
|
|
|
35 |
1S |
p. S95
|
artikel
|
| 71 |
P105 - BDE-99 reprograms the liver epigenome persistnently altering the transcriptome
|
Dempsey, Joseph
|
|
|
35 |
1S |
p. S54
|
artikel
|
| 72 |
P176 - Binding proteins have enzyme specific effects on xenobiotic metabolism
|
Yabut, King
|
|
|
35 |
1S |
p. S76-S77
|
artikel
|
| 73 |
P151 - Bioactivation of halogenated aromatic drugs into quinone metabolites as precursors to drug-induced hepatotoxicity
|
Davis, Mary A.
|
|
|
35 |
1S |
p. S68
|
artikel
|
| 74 |
P189 - Bioinformatic analysis of common non-synonymous single nucleotide variants in cytochrome P450 pharmacogenes
|
Chong, Cheng Shoong
|
|
|
35 |
1S |
p. S80
|
artikel
|
| 75 |
P18 - Biotransformation of methoxylated bromodiphenyl ether natural products
|
James, Margaret
|
|
|
35 |
1S |
p. S27
|
artikel
|
| 76 |
P179 - Cell-type specific metabolism of isoniazid in the liver
|
Zhu, Junjie
|
|
|
35 |
1S |
p. S77
|
artikel
|
| 77 |
P167 - Characterization of differential metabolic routes of tienilic acid and its 3-thiophene isomer with ion mobility enabled mass spectrometry
|
Mullin, Lauren
|
|
|
35 |
1S |
p. S73-S74
|
artikel
|
| 78 |
P55 - Characterization of in vivo disposition of CTI-1601: A mitochondria targeted therapy for friedreich’s ataxia
|
Gonzalez, Eric
|
|
|
35 |
1S |
p. S38
|
artikel
|
| 79 |
P97 - Clinical prediction of drug-drug interaction risk due to time-dependent inhibition of cytochrome P450 3A4 - A side-by-side comparison of human liver microsome and hepatocyte
|
Tseng, Elaine
|
|
|
35 |
1S |
p. S52
|
artikel
|
| 80 |
P122 - Combination of data-driven and mechanism based approach for prediction of human intestinal absorption
|
Handa, Koichi
|
|
|
35 |
1S |
p. S59-S60
|
artikel
|
| 81 |
P32 - Comparative metabolism of 14C-AQX-1125 following oral administration to rats, dogs and humans
|
Barton, Eleanor
|
|
|
35 |
1S |
p. S30-S31
|
artikel
|
| 82 |
P177 - Comparative metabolism of [14C]-BMS-986165 in mice, rats, monkey, and humans
|
Yao, Ming
|
|
|
35 |
1S |
p. S77
|
artikel
|
| 83 |
P6 - Comparison of techniques to assess non-specific microsomal binding
|
Chan, Tom
|
|
|
35 |
1S |
p. S24
|
artikel
|
| 84 |
P60 - Comparison of toxicity and permeability among angiotensin receptor blockers to the fetus
|
Nishimura, Tomohiro
|
|
|
35 |
1S |
p. S40
|
artikel
|
| 85 |
P132 - Contribution of fetal liver and placenta to maternal-fetal oxycodone disposition
|
Shum, Sara
|
|
|
35 |
1S |
p. S62-S63
|
artikel
|
| 86 |
P92 - Correlation between cytochrome P450 inducers and nuclear receptor activation- A screening approach
|
Roychowdhury, Shantanu
|
|
|
35 |
1S |
p. S50
|
artikel
|
| 87 |
P98 - Delineation of in vitro cut-off values for CYP3A4/5 time dependent inhibition useful in early drug design – a side-by-side comparison in human liver microsomes and hepatocytes
|
Eng, Heather
|
|
|
35 |
1S |
p. S52
|
artikel
|
| 88 |
P19 - Design and characterization of selective mechanism-based inhibitors of CYP4Z1
|
Kowalski, John
|
|
|
35 |
1S |
p. S27-S28
|
artikel
|
| 89 |
P45 - Determination and comparison of skin and plasma concentrations of multikinase inhibitors and their active metabolites in mice
|
Kojima, Ayaka
|
|
|
35 |
1S |
p. S34-S35
|
artikel
|
| 90 |
P91 - Determination of additive, synergistic and antagonistic effects by the analyses of protein markers in pesticide mixture-treated heparg-cells
|
Schmidt, Felix
|
|
|
35 |
1S |
p. S50
|
artikel
|
| 91 |
P52 - Determination of aminoglycoside toxicity in human renal proximal tubule monolayers using clinical relevant biomarkers of nephrotoxicity
|
Brown, Colin
|
|
|
35 |
1S |
p. S37
|
artikel
|
| 92 |
P163 - Determination of intrinsic clearance of low turnover drugs using HuREL hepatocyte co-cultures
|
Nookala, Anantha Ram
|
|
|
35 |
1S |
p. S72-S73
|
artikel
|
| 93 |
P205 - Determination of permeability across Caco-2 cell monolayer and development of predictable equations for oral absorbability of general chemical substances
|
Kamiya, Yusuke
|
|
|
35 |
1S |
p. S84
|
artikel
|
| 94 |
P219 - Developing a class of orally active drugs with unusual in vitro ADME properties: The role of PBPK modelling in the discovery process
|
Stefani, Mariarita
|
|
|
35 |
1S |
p. S89
|
artikel
|
| 95 |
P138 - Developing a novel 3-dimensional small intestinal-like model for xenobiotic screening
|
Jochems, Paulus
|
|
|
35 |
1S |
p. S64-S65
|
artikel
|
| 96 |
P216 - Development and verification of a linked THC/11-OH-THC PBPK model in healthy subjects and extrapolation to pregnancy
|
Unadkat, Jashvant D.
|
|
|
35 |
1S |
p. S88
|
artikel
|
| 97 |
P1 - Development of a highly sensitive LC/MS/MS assay for pegylated FGF21 protein measurement from biological matrices
|
Gu, Xiaomei
|
|
|
35 |
1S |
p. S23
|
artikel
|
| 98 |
P59 - Development of a novel profile data analysis method to aid deep understanding of pharmacodynamics by decomposing the complex effects of a drug
|
Mizuno, Tadahaya
|
|
|
35 |
1S |
p. S39-S40
|
artikel
|
| 99 |
P210 - Development of a physiologially based pharmacokinetic model to predict changes in exposure of a circulating metabolite with CYP3A4 induction
|
Cabalu, Tamara
|
|
|
35 |
1S |
p. S86
|
artikel
|
| 100 |
P62 - Development of LC-MS/MS methods for the quantitation of commonly co-administered drugs and an assessment of the impact of their presence on the analysis and stability of novel drug candidates in support of a clinical study
|
Schmich, Ryan
|
|
|
35 |
1S |
p. S40
|
artikel
|
| 101 |
P16 - Drug-induced liver injury alters expression and activities of drug-metabolizing cytochrome P450 enzymes in mouse liver at different ages
|
Bao, Yifan
|
|
|
35 |
1S |
p. S26-S27
|
artikel
|
| 102 |
P21 - Drug library screening for human CYP1A1 substrates
|
Lang, Dieter
|
|
|
35 |
1S |
p. S28
|
artikel
|
| 103 |
P119 - Drug-metabolizing activity and cytochromes P450 induction in human hepatocytes from TK-NOG chimeric mice with humanized livers
|
Uehara, Shotaro
|
|
|
35 |
1S |
p. S58-S59
|
artikel
|
| 104 |
P20 - Dual effects of methylated indoles on CYP1A1 in human hepatocytes
|
Vyhlidalova, Barbora
|
|
|
35 |
1S |
p. S28
|
artikel
|
| 105 |
P121 - Early development of idiosyncratic drug-induced liver injury in an impaired immune checkpoint mouse model
|
Jee, Alison
|
|
|
35 |
1S |
p. S59
|
artikel
|
| 106 |
P155 - Early life exposure to environmental contaminants (BDE-47, TBBPA, AND BPS) produced persistent gut dysbiosis in adult male mice
|
Gomez, Matthew
|
|
|
35 |
1S |
p. S70
|
artikel
|
| 107 |
P23 - Effect of dexamethasone treatment on cytochrome P450 3A-UDP-glucuronosyltransferase 1A interactions in rat liver
|
Miyauchi, Yuu
|
|
|
35 |
1S |
p. S28-S29
|
artikel
|
| 108 |
P14 - Effect of the CYP2C8*3 variant on asthma symptom control and montelukast efficacy
|
Almestica, Marysol
|
|
|
35 |
1S |
p. S26
|
artikel
|
| 109 |
P9 - Effects of histone deacetylase inhibitor on UGT1A1 and UGT1A6 expression in CACO-2 cells
|
Katoh, Miki
|
|
|
35 |
1S |
p. S25
|
artikel
|
| 110 |
P252 - Effects of O,P′-DDT, P,P′-DDT and endosulfan on the expression of hormone-sensitive microrna in MCF-7 cells
|
Gulyaeva, Lyudmila
|
|
|
35 |
1S |
p. S99
|
artikel
|
| 111 |
P108 - Effects of organic solvents on pravastatin uptake in human hepatocytes
|
Li, Albert P.
|
|
|
35 |
1S |
p. S55
|
artikel
|
| 112 |
P188 - Effects of RNA editing on expression and function of human aldo-keto reductase family 1 member C (AKR1C)
|
Morita, Koki
|
|
|
35 |
1S |
p. S79-S80
|
artikel
|
| 113 |
P79 - Effects of the Pregnane X Receptor (PXR) activator rifampin on transporter gene expressions: Studies in hepatocytes in vitro and in monkeys in in vivo
|
Niu, Congrong
|
|
|
35 |
1S |
p. S46
|
artikel
|
| 114 |
P22 - Endobiotics for phenotyping of human cytochrome P450 enzymes: Use of metabolomics for the identification of new CYP2D6 endogenous biomarkers on healthy volunteers
|
Desmeules, Jules
|
|
|
35 |
1S |
p. S28
|
artikel
|
| 115 |
P54 - Endoplasmic reticulum stress suppress motility and metabolism of prostate cancer cells: Uncovering enterolactone’s mechanisms of action
|
De Silva, Franklyn
|
|
|
35 |
1S |
p. S38
|
artikel
|
| 116 |
P241 - Establishment of a complete in vitro drug transporter panel to meet regulatory guidelines
|
Gao, Chunying
|
|
|
35 |
1S |
p. S96
|
artikel
|
| 117 |
P152 - Establishment of hepatocyte model for poor metabolizer using genetically manipulated human IPS cells
|
Deguchi, Sayaka
|
|
|
35 |
1S |
p. S68-S69
|
artikel
|
| 118 |
P133 - Evaluating stability of human monoclonal antibody in cultured rat hepatocytes with a surrogate peptide appro
|
Galeva, Nadya
|
|
|
35 |
1S |
p. S63
|
artikel
|
| 119 |
P73 - Evaluation for inhibitory potential of ginsenoside-RH2 epimers on breast cancer resistance protein (BCRP)-mediated efflux
|
Jo, Seongjun
|
|
|
35 |
1S |
p. S44
|
artikel
|
| 120 |
P134 - Evaluation of CRISPR-CAS9 and CRISPR-CAS13 in modulating drug metabolizing enzymes
|
Chen, Lisa
|
|
|
35 |
1S |
p. S63-S64
|
artikel
|
| 121 |
P104 - Evaluation of cytochrome P450 selectivity for hydralazine as an aldehyde oxidase inhibitor for reaction phenotyping
|
Yang, Xin
|
|
|
35 |
1S |
p. S53-S54
|
artikel
|
| 122 |
P74 - Evaluation of endogenous biomarkers of OATP1B activity in patients with non-small cell lung cancer who receive paclitaxel
|
Kusuhara, Hiroyuki
|
|
|
35 |
1S |
p. S44
|
artikel
|
| 123 |
P142 - Evaluation of fraction unbound across five species and seven tissues and the impact of low temperature
|
Ryu, Sangwoo
|
|
|
35 |
1S |
p. S65-S66
|
artikel
|
| 124 |
P200 - Evaluation of levornidazole phosphate pharmacokinetics and pharmacodynamics for early dosing optimization
|
Wei, Minji
|
|
|
35 |
1S |
p. S83
|
artikel
|
| 125 |
P96 - Evaluation of methotrexate and idelalisib as inducers of human aldehyde oxidase in cellular models
|
Yeap, Szu Ling
|
|
|
35 |
1S |
p. S51-S52
|
artikel
|
| 126 |
P130 - Evaluation of potential early-life sensitivity using life-stage physiologically based pharmacokinetics modeling with in vitro to in vivo extrapolation
|
Mallick, Pankajini
|
|
|
35 |
1S |
p. S62
|
artikel
|
| 127 |
P143 - Evaluation of single-use rapid equilibrium dialysis [red] device for automated octanol-water partitioning (LOGD7.4) assay to assess the lipophilicity of drug compounds
|
Sheldon, Adrian
|
|
|
35 |
1S |
p. S66
|
artikel
|
| 128 |
P66 - Evaluation of species differences in major clearance pathways between humans and animals
|
Yamauchi, Saki
|
|
|
35 |
1S |
p. S42
|
artikel
|
| 129 |
P11 - Expanding the phenotyping tool kit for glutathione S-transferases
|
Strelevitz, Timothy
|
|
|
35 |
1S |
p. S25
|
artikel
|
| 130 |
P140 - Expansion of in vitro drug metabolism assay capacity and efficiency with high throughput screening using automated liquid handling
|
Schofield, Andrew
|
|
|
35 |
1S |
p. S65
|
artikel
|
| 131 |
P38 - Exploring species differences in aldehyde oxidase activity
|
Shah, Pranav
|
|
|
35 |
1S |
p. S32-S33
|
artikel
|
| 132 |
P183 - Exposure to cadmium modulates the composition of short chain fatty acid-producing microbiota in an alzheimer’s disease mouse model
|
Zhang, Angela
|
|
|
35 |
1S |
p. S78
|
artikel
|
| 133 |
P63 - Fast-acting small molecules inhibiting malaria infection at multiple life stages
|
Singh, Snigdha
|
|
|
35 |
1S |
p. S40-S41
|
artikel
|
| 134 |
P238 - Functional investigation of solute carrier family 35 member F2 (SLC35F2) as a drug transporter in the blood-brain barrier
|
Mochizuki, Tatsuki
|
|
|
35 |
1S |
p. S95
|
artikel
|
| 135 |
P162 - Further characterization of hepatopac – non-targeted metabolite-profiling of 7 chemicals including slow clearance chemicals and metabolism-mediated toxicity
|
Lee, Mi-Young
|
|
|
35 |
1S |
p. S72
|
artikel
|
| 136 |
P208 - Generation of high-purity human IPS cell-derived intestinal epithelial cells for pharmaceutical research
|
Takayama, Kazuo
|
|
|
35 |
1S |
p. S85-S86
|
artikel
|
| 137 |
P171 - Hepatic metabolism of benzalkonium chloride disinfectants by CYP2D6 and CYP4 family members
|
Seguin, Ryan
|
|
|
35 |
1S |
p. S75
|
artikel
|
| 138 |
P94 - High throughput LCMS quantification of cytochrome P450 proteins in plated human hepatocytes direct from 96-well plates
|
Savaryn, John
|
|
|
35 |
1S |
p. S51
|
artikel
|
| 139 |
P199 - HILIC UPLC-MS/MS methods for the assessment of hydroxynorketamines pharmacokinetics in mouse plasma and brain
|
Wang, Amy Q.
|
|
|
35 |
1S |
p. S82-S83
|
artikel
|
| 140 |
P43 - Human and animal ADME using WS-cavity ring-down spectroscopy
|
Dueker, Stephen
|
|
|
35 |
1S |
p. S34
|
artikel
|
| 141 |
P192 - Identification of genetic determinants for central pain sensitization in fibromyalgia patients
|
Gloor, Yvonne
|
|
|
35 |
1S |
p. S81
|
artikel
|
| 142 |
P17 - Impact of age on CYP450 activities in bovine liver, lung and kidney
|
Hu, Steven
|
|
|
35 |
1S |
p. S27
|
artikel
|
| 143 |
P117 - Impact of culture conditions on functional expression of major drug metabolizing enzymes and transporters in long-term UPCYTE® hepatocyte culture
|
Schaefer, Michelle
|
|
|
35 |
1S |
p. S58
|
artikel
|
| 144 |
P80 - Impact of piperine on carbamazepine: Modeling-based pharmacokinetics analysis and pharmacodynamics evaluation in animal models
|
Ren, Tianjing
|
|
|
35 |
1S |
p. S46
|
artikel
|
| 145 |
P165 - Improved on-line accelerator mass spectrometry techniques for the analysis of environmental chemicals at ultra-low exposure levels
|
Malfatti, Michael
|
|
|
35 |
1S |
p. S73
|
artikel
|
| 146 |
P150 - Increased identification of low abundant metabolites utilizing automatic background exclusion and specific filtering features of orbitrap ID-X tribrid mass spectrometer
|
Comstock, Kate
|
|
|
35 |
1S |
p. S68
|
artikel
|
| 147 |
P230 - Increase in renal exposure to imatinib during cholestasis in mice
|
Kawanishi, Takumi
|
|
|
35 |
1S |
p. S92
|
artikel
|
| 148 |
P247 - indoxyl sulfate albumin-facilitated transport via renal drug transporter OAT1 – translation from microfluidic in vitro system to healthy and subjects with severe kidney disease
|
van der Made, Thom
|
|
|
35 |
1S |
p. S98
|
artikel
|
| 149 |
P8 - Interspecies differences in renal clearance based on physicochemical drug properties
|
Jansen, Katja
|
|
|
35 |
1S |
p. S24-S25
|
artikel
|
| 150 |
P214 - Investigating the impact of enzyme correlations on inter-individual variability in pharmacokinetics and drug-drug interactions
|
Hatley, Oliver
|
|
|
35 |
1S |
p. S87
|
artikel
|
| 151 |
P196 - Investigating the tissue distribution of [14C]-prucalopride following a single oral dose in rats
|
Welty, Devin
|
|
|
35 |
1S |
p. S82
|
artikel
|
| 152 |
P226 - Investigating uremic solute-drugs interaction using in vitro transporter assays
|
Chang, Shih-Yu
|
|
|
35 |
1S |
p. S90-S91
|
artikel
|
| 153 |
P244 - Investigation of interindividual variability in kidney drug transporter expression and function by utilizing non-invasive urinary exosomes and endogenous biomarkers
|
Shi, Yuanyuan
|
|
|
35 |
1S |
p. S97
|
artikel
|
| 154 |
P245 - Investigation of renal drug secretion in a kidney-on-a-chip model
|
Stahl, Simone
|
|
|
35 |
1S |
p. S97
|
artikel
|
| 155 |
P86 - Investigation of the interaction mechanism between metronidazole and 5-fluorouracil
|
Yamagishi, Yoshiaki
|
|
|
35 |
1S |
p. S48
|
artikel
|
| 156 |
P61 - Investigations into definitive in vitro DDI assays to satisfy FDA guidelines
|
MacArthur, Taylor
|
|
|
35 |
1S |
p. S40
|
artikel
|
| 157 |
P145 - In vitro absorption and metabolism of 7-O-succinyl macrolactin a in human
|
Bae, Soo Hyeon
|
|
|
35 |
1S |
p. S66-S67
|
artikel
|
| 158 |
P235 - In vitro development of folate transport and endocytosis by PCFT, RFC, and FRα, in a transwell system
|
Zhang, Xuexiang “John”
|
|
|
35 |
1S |
p. S93-S94
|
artikel
|
| 159 |
P120 - In-vitro evaluation of primary animal hepatic function using a 3D-spheroid culture system
|
Tritapoe, Julia
|
|
|
35 |
1S |
p. S59
|
artikel
|
| 160 |
P100 - In vitro evaluation of UDP-glucuronosyltransferase (UGT) 1A3 and UGT2B4 inhibition
|
Lapham, Kimberly
|
|
|
35 |
1S |
p. S52-S53
|
artikel
|
| 161 |
P242 - In vitro functional characterization of rare genetic variants in hepatic bile acid and drug transporter NTCP
|
Russell, Laura
|
|
|
35 |
1S |
p. S96
|
artikel
|
| 162 |
P85 - In vitro inhibitory effect of tricyclic antidepressants on human liver microsomal morphine glucuronidation
|
Uchaipichat, Verawan
|
|
|
35 |
1S |
p. S48
|
artikel
|
| 163 |
P76 - In vitro inhibitory effects of APINACA, a synthetic cannabinoid, on human cytochrome P450, UDP-glucuronosyltransferase enzymes, and drug transporterS
|
Kim, Sunjoo
|
|
|
35 |
1S |
p. S45
|
artikel
|
| 164 |
P75 - In vitro inhibitory effects of ZIZIPHI SPINOSI semen extract on cytochrome P450 and UDP-glucuronosyltransferase enzymes activities in human liver microsomes
|
Lee, Chae Bin
|
|
|
35 |
1S |
p. S44-S45
|
artikel
|
| 165 |
P148 - In vitro mechanistic investigation studies to understand the metabolic fate of compound 1
|
Bowlin, Steve
|
|
|
35 |
1S |
p. S67
|
artikel
|
| 166 |
P78 - In vitro metabolic, CYP and transporter characterization of PTI-125, a novel small molecule drug candidate for ALZHEIMER’S disease
|
Luo, Gang
|
|
|
35 |
1S |
p. S45-S46
|
artikel
|
| 167 |
P156 - In vitro metabolism of bardoxolone, an activator of NRF2 via reversible covalent modification of KEAP1: Formation of bardoxolone epoxide and novel metabolic pathway for oxidative denitrilation via reductive addition of glutathione
|
Kamel, Amin
|
|
|
35 |
1S |
p. S70
|
artikel
|
| 168 |
P160 - In vitro metabolism of endosulfan sulfate in human liver microsomes, S9 fractions and hepatocytes
|
Lee, Hwa-Kyung
|
|
|
35 |
1S |
p. S71-S72
|
artikel
|
| 169 |
P77 - In vitro metabolism of ticagrelor and its metabolic interactions with statins
|
Liu, Shuaibing
|
|
|
35 |
1S |
p. S45
|
artikel
|
| 170 |
P128 - In vitro to in vivo extrapolation (IVIVE) for low intrinsic clearance compounds
|
KC, Gaurab
|
|
|
35 |
1S |
p. S61
|
artikel
|
| 171 |
P129 - In-vivo transporter-mediated hepatic clearance of rosuvastatin in humans could be better predicted using transporter-expressing cells than hepatocytes
|
Kumar, Vineet
|
|
|
35 |
1S |
p. S61-S62
|
artikel
|
| 172 |
P172 - I-screen: An ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent
|
van de Steeg, Evita
|
|
|
35 |
1S |
p. S75-S76
|
artikel
|
| 173 |
P224 - Isopropanol-trifluoroacetic acid extraction selectively depletes albumin from liver homogenate and plasma: Application in DMET proteomic analysis
|
Karasu, Matt
|
|
|
35 |
1S |
p. S90
|
artikel
|
| 174 |
P211 - Iterative development and verification of a middle-out PBPK model for abiraterone
|
Yi Cheong, Eleanor Jing
|
|
|
35 |
1S |
p. S86
|
artikel
|
| 175 |
P99 - LC-MS/MS based bioanalysis method for bilirubin glucuronides: Application in UGT1A1 inhibition evaluation and comparison with data obtained using estradiol
|
Han, Chunyan
|
|
|
35 |
1S |
p. S52
|
artikel
|
| 176 |
P194 - Ligand-free estrogen receptor alpha (ESR1) as master regulator for the expression of CYP3A4 and other cytochrome P450S (CYP) in human liver
|
Wang, Danxin
|
|
|
35 |
1S |
p. S81
|
artikel
|
| 177 |
P87 - Main mechanisms of pharmacokinetic drug-drug interactions triggering label recommendations for drugs approved by the food and drug administration in 2018
|
Yu, Jingjing
|
|
|
35 |
1S |
p. S49
|
artikel
|
| 178 |
P42 - Maternal-fetal pharmacokinetics of bupropion and its metabolites
|
Czuba, Lindsay
|
|
|
35 |
1S |
p. S33-S34
|
artikel
|
| 179 |
P203 - Mathematical pharmacokinetic modeling to interpret metabolic pathway of decursin, decursinol angelate and decursinol
|
Choi, Go-Wun
|
|
|
35 |
1S |
p. S84
|
artikel
|
| 180 |
P144 - Mechanistic insights into the human ADME of a therapeutic candidate
|
Aloysius, Herve
|
|
|
35 |
1S |
p. S66
|
artikel
|
| 181 |
P39 - Metabolism of desloratadine in TK-NOG chimeric mice with humanized livers
|
Uehara, Shotaro
|
|
|
35 |
1S |
p. S33
|
artikel
|
| 182 |
P168 - Methods to detect and enrich trimethoprim protein adducts in biological matrices
|
Nolte, Whitney
|
|
|
35 |
1S |
p. S74
|
artikel
|
| 183 |
P170 - Microtracer bioavailability, biotransformation mechanisms, and excretion of the covalent BTK inhibitor acalabrutinib in humans
|
Podoll, Terry
|
|
|
35 |
1S |
p. S74-S75
|
artikel
|
| 184 |
P124 - Molecular determinants of the inherently slow entry of NKTR-181 into the brain
|
Odinecs, Aleksandrs
|
|
|
35 |
1S |
p. S60
|
artikel
|
| 185 |
P246 - Nephrotoxicity in MATE1, MATE2K and MATE1/2K knockout cell lines following treatment with cisplatin using the mimetas 3D organoplate platform
|
Steiner, Toni
|
|
|
35 |
1S |
p. S97-S98
|
artikel
|
| 186 |
P126 - Observed vs. predicted effects of protein binding: Improving in vivo predictions of hepatic clearance, intracellular concentration and IC50 values
|
Brouwer, Kenneth
|
|
|
35 |
1S |
p. S60-S61
|
artikel
|
| 187 |
P131 - Optimization and validation of rodent chemical knock out model for P-glycoprotein using the selective inhibitor, valspodar, and application to internal cut-off values and calibration of MDCK-MDR1 Cell line
|
Rowbottom, Christopher
|
|
|
35 |
1S |
p. S62
|
artikel
|
| 188 |
P136 - Optimization of 3D liver spheroid culture conditions of individual hepatocyte donors and pooled hepatocyte donors
|
Cossis, Casey
|
|
|
35 |
1S |
p. S64
|
artikel
|
| 189 |
P139 - Optimization of heparg workflow for use in 3D spheroid models
|
Millett, Michael
|
|
|
35 |
1S |
p. S65
|
artikel
|
| 190 |
P135 - Optimization of non-parenchymal and hepatocyte co-culture model
|
Cossis, Casey
|
|
|
35 |
1S |
p. S64
|
artikel
|
| 191 |
P178 - Optimization of sample processing for metabolism studies of targeted covalent inhibitors (TCI)
|
Zhang, Chenghong
|
|
|
35 |
1S |
p. S77
|
artikel
|
| 192 |
P3 - Optimization of the sample collection procedures for selective BCRP inhibitor, KO143, in rodents
|
Pietrasiewicz, Alicia
|
|
|
35 |
1S |
p. S23-S24
|
artikel
|
| 193 |
Poster Details
|
|
|
|
35 |
1S |
p. S100-S113
|
artikel
|
| 194 |
P212 - PBPK modeling and simulation of morphine in virtual neonates generated using actual patient information
|
Emoto, Chie
|
|
|
35 |
1S |
p. S86-S87
|
artikel
|
| 195 |
P36 - Perinatal BDE-47 exposure altered the developmental trajectory of gut microbiota in rats
|
Gillette, Joanna
|
|
|
35 |
1S |
p. S32
|
artikel
|
| 196 |
P193 - Persistent regulation of hepatic non-coding RNAS following neonatal exposure to BPA, BDE-99, and PCBS
|
Lim, Joe
|
|
|
35 |
1S |
p. S81
|
artikel
|
| 197 |
P229 - P-glycoprotein activation mechanism by snail-induced epithelial-to-mesenchymal transition in lung cancer cells
|
Kamioka, Hiroki
|
|
|
35 |
1S |
p. S91-S92
|
artikel
|
| 198 |
P204 - Pharmacokienetics for bioactive compounds after oral administration of sosihotang soft-extract to humans
|
Choi, Eun-Jeong
|
|
|
35 |
1S |
p. S84
|
artikel
|
| 199 |
P82 - Pharmacokinetic application of normothermic perfused ex vivo porcine and diseased human livers
|
Stevens, Lianne
|
|
|
35 |
1S |
p. S47
|
artikel
|
| 200 |
P69 - Pharmacokinetic interaction study of novel combination of HMG co-a reductase inhibitor with green coffee bean formulation for obesity associated complications in SD rats using UHPLC/QTOF/MS
|
Bolla, Lavanya
|
|
|
35 |
1S |
p. S42
|
artikel
|
| 201 |
P227 - Pharmacokinetics of GDC-0810 and its interaction with coproporphyrin i in the first-in-human, ascending dose study in women with locally advanced or metastatic estrogen receptor positive breast cancer
|
Kathy Cheung, Kit Wun
|
|
|
35 |
1S |
p. S91
|
artikel
|
| 202 |
P206 - Pharmacokinetic studies of asarinin, β-eudesmol, and wogonin in rats using a validated simultaneous UPLC-MS/MS method
|
Lee, Yong-Bok
|
|
|
35 |
1S |
p. S85
|
artikel
|
| 203 |
P186 - pH dependent CES1 mediated hydrolysis of vixotrigine in human liver microsomes
|
Johnson, Joshua
|
|
|
35 |
1S |
p. S79
|
artikel
|
| 204 |
P243 - Physiologically-based pharmacokinetic modelling of transporter-mediated hepatic disposition using the imaging biomarker gadoxetate
|
Scotcher, Daniel
|
|
|
35 |
1S |
p. S96
|
artikel
|
| 205 |
P217 - Physiologically-based pharmacokinetic (PBPK) modeling of liposomal compound x - deciphering the mystery of liposomal delivery
|
Qian, Lian
|
|
|
35 |
1S |
p. S88
|
artikel
|
| 206 |
P202 - Population pharmacokinetic and pharmacodynamic properties of eptifibatide in the inhibition of platelet aggregation in healthy Chinese subjects
|
Li, Qinmei
|
|
|
35 |
1S |
p. S83-S84
|
artikel
|
| 207 |
P223 - PPB: Considerations for safety studies and data interpretation
|
Pajkovic, Natasa
|
|
|
35 |
1S |
p. S90
|
artikel
|
| 208 |
P125 - Predicting PKA using a combination of quantum and machine learning methods
|
Hunt, Peter
|
|
|
35 |
1S |
p. S60
|
artikel
|
| 209 |
P102 - Predicting risk of cardiac arrhythmias based on inhibitory potencies (Ki) against CYP2J2-mediated arachidonic acid metabolism
|
Hui Leow, Jacqueline Wen
|
|
|
35 |
1S |
p. S53
|
artikel
|
| 210 |
P127 - Prediction of brain disposition in rat and human from in vitro data: Correction of passive permeation
|
Nicolaï, Johan
|
|
|
35 |
1S |
p. S61
|
artikel
|
| 211 |
P232 - Prediction of hepatic clearance and partitioning in rat for improved BSEP inhibition risk assessment in humans
|
Kolur, Anil
|
|
|
35 |
1S |
p. S92-S93
|
artikel
|
| 212 |
P71 - Prediction of P-GP mediated drug-drug interaction at the blood-brain barrier
|
Chapy, Hélène
|
|
|
35 |
1S |
p. S43
|
artikel
|
| 213 |
P112 - Primary human hepatocyte 3D spheroids for studying hepatic function and drug metabolism
|
Lahiri, Sujoy
|
|
|
35 |
1S |
p. S56
|
artikel
|
| 214 |
P115 - Protein recovery and quantification of drug metabolizing enzymes and transporters in membrane extracts prepared by differential detergent fractionation: Comparison with established methods
|
Qasem, Rani
|
|
|
35 |
1S |
p. S57
|
artikel
|
| 215 |
P169 - Pyrrolizidine alkaloid DNA adduct formation and the interplay between uptake, metabolism, and efflux in rat sandwich cultured hepatocytes
|
Obringer, Cindy
|
|
|
35 |
1S |
p. S74
|
artikel
|
| 216 |
P158 - Qualitative metabolite profiling of drug candidates in human liver microtissue systems in support of drug discovery projects
|
King, Lloyd
|
|
|
35 |
1S |
p. S71
|
artikel
|
| 217 |
P233 - Quantification of pravastatin uptake into rat, dog, monkey and human plated cryopreserved hepatocytes in the presence and absence of bovine serum albumin
|
Li, Albert P.
|
|
|
35 |
1S |
p. S93
|
artikel
|
| 218 |
P56 - Quantitation of a novel enolase-2 selective inhibitor prodrug BIS-POM-HEX, its intermediate HEMI-POM-HEX, and parent drug HEX in mouse plasma and brain tissues using liquid chromatography coupled with tandem mass spectrometry
|
Jiang, Yongying
|
|
|
35 |
1S |
p. S38-S39
|
artikel
|
| 219 |
P2 - Quantitative analysis of a thyroid hormone biomarker extracted from whole blood using a mitra microsampling device
|
Watts, Jason
|
|
|
35 |
1S |
p. S23
|
artikel
|
| 220 |
P141 - Quantitative and mechanistic comparison of fraction unbound from liver homogenates and hepatocytes at 4°C and applications in KPUU determination
|
Riccardi, Keith
|
|
|
35 |
1S |
p. S65
|
artikel
|
| 221 |
P161 - Quantitative metabolic profiling of slowly cleared chemicals in in vitro models including 3D liver spheroid and hepatopac and hepatic clearance predictions from in vitro data using gastroplus PBPK modelling following topical application
|
Lee, Mi-Young
|
|
|
35 |
1S |
p. S72
|
artikel
|
| 222 |
P72 - Quantitative prediction of CYP3A4 and CYP3A5-mediated drug drug interactions
|
Guo, Yingying
|
|
|
35 |
1S |
p. S43-S44
|
artikel
|
| 223 |
P218 - Quantitative prediction of oral drug absorption by kinetically analyzing gastrointestinal water dynamics
|
Shirasaka, Yoshiyuki
|
|
|
35 |
1S |
p. S88-S89
|
artikel
|
| 224 |
P41 - Quantitative tissue distribution of conjugated and free payload in tumor bearing mice after intravenous dosing of glypican 3-targeting adnectiin drug conjugate
|
Chen, Weiqi
|
|
|
35 |
1S |
p. S33
|
artikel
|
| 225 |
P50 - Quantitative whole body autoradiography of 14C-ENV-101 in cynomolgus monkey
|
Webber, Guy
|
|
|
35 |
1S |
p. S36-S37
|
artikel
|
| 226 |
P31 - Rates and routes of excretion of 14C-AQX-1125 following oral administration to rats, dogs and humans
|
Cooke, Ray
|
|
|
35 |
1S |
p. S30
|
artikel
|
| 227 |
P34 - Rates and routes of excretion of 14C-eravacycline following administration to rats and humans
|
Cooke, Ray
|
|
|
35 |
1S |
p. S31
|
artikel
|
| 228 |
P118 - Reaction phenotyping of low turnover compounds through persistent inhibition of cytochromes P450 in long term cultures with human hepatopac
|
Smith, Sheri
|
|
|
35 |
1S |
p. S58
|
artikel
|
| 229 |
P114 - Recovery of drug metabolizing enzyme and transporter gene expression in prolonged cultures of confluent 2D-human hepatocyte cultures
|
Li, Albert P.
|
|
|
35 |
1S |
p. S57
|
artikel
|
| 230 |
P48 - Regional intestinal disposition of desaminotyrosine, an immunomodulatory microbial metabolite of flavonoids
|
Singh, Rashim
|
|
|
35 |
1S |
p. S36
|
artikel
|
| 231 |
P215 - Risk assessment in humans using physiologically based pharmacokinetic model of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate: Development and evaluation of model
|
Lee, Yong-Bok
|
|
|
35 |
1S |
p. S87-S88
|
artikel
|
| 232 |
P88 - Role of micrornas in drug-induced epithelial-mesenchymal transition in human lung-derived alveolar type II epithelial cell model A549/ABCA3
|
Yumoto, Ryoko
|
|
|
35 |
1S |
p. S49
|
artikel
|
| 233 |
P51 - Routine metabolite identification for complex cyclic peptides based on ims enabled qtof dia data acquisition and mass-metasite data processing
|
Alelyunas, Yun
|
|
|
35 |
1S |
p. S37
|
artikel
|
| 234 |
P201 - Safety, pharmacokinetics and pharmacodynamics effects of multiple-dose administration of fotagliptin benzoate-dipeptidyl peptidase-4 inhibitor in type 2 diabetes mellitus
|
Wu, Min
|
|
|
35 |
1S |
p. S83
|
artikel
|
| 235 |
P37 - Safety, pharmacokinetics and pharmacodynamics evaluation of chiglitazar, a novel identified PPAR pan-agonist for the treatment of type 2 diabetes in different age groups
|
Li, Xiaojiao
|
|
|
35 |
1S |
p. S32
|
artikel
|
| 236 |
P236 - Screening of endogenous OCTs substrates applicable for prediction of drug interactions
|
Masuo, Yusuke
|
|
|
35 |
1S |
p. S94
|
artikel
|
| 237 |
P89 - SIMCYP PBPK modeling and simulation of pharmacokinetic drug interaction between lorlatinib and itraconazole: A case study using induction slope
|
Lin, Jian
|
|
|
35 |
1S |
p. S49
|
artikel
|
| 238 |
P248 - Simulations of noncompetitive substrate transport
|
Wagner, David
|
|
|
35 |
1S |
p. S98
|
artikel
|
| 239 |
P33 - Species differences in the mass balance, excretion and metabolism of [14C] LY3202626 in human, dog and rat
|
Cassidy, Ken
|
|
|
35 |
1S |
p. S31
|
artikel
|
| 240 |
P70 - Stereoselective inhibitory potentials of ginsenoside-rh2 epimers toward organic anion transporting polypeptide (OATP) 1B1/3-mediated uptake
|
Chae, Soon Uk
|
|
|
35 |
1S |
p. S43
|
artikel
|
| 241 |
P64 - Strategies and considerations for human PK optimisation and prediction in drug discovery: Clearance
|
Williamson, Beth
|
|
|
35 |
1S |
p. S41
|
artikel
|
| 242 |
P65 - Strategies and considerations for human PK optimisation and prediction in drug discovery: Volume of distribution and oral absorption
|
Williamson, Beth
|
|
|
35 |
1S |
p. S41
|
artikel
|
| 243 |
P147 - Structural elucidation of the major human metabolites of viloxazine
|
Barton, Eleanor
|
|
|
35 |
1S |
p. S67
|
artikel
|
| 244 |
P187 - Structure-activity relationship of atorvastatin derivatives for metabolic activation by human carboxylesterase
|
Mizoi, Kenta
|
|
|
35 |
1S |
p. S79
|
artikel
|
| 245 |
P231 - Study to assess the food effect on plasma levels of emerging endogenous biomarkers of transporter mediated drug-drug interactions
|
King-Ahmad, Amanda
|
|
|
35 |
1S |
p. S92
|
artikel
|
| 246 |
P240 - Substrate recognition and chloride ion dependent transport of angiothensin II receptor blockers by OAT4
|
Noguchi, Saki
|
|
|
35 |
1S |
p. S95-S96
|
artikel
|
| 247 |
P191 - The CYP2D6 ‘enhancer’ SNP: Long-range linkage analysis and impact on activity in human liver tissue
|
Gaedigk, Andrea
|
|
|
35 |
1S |
p. S80-S81
|
artikel
|
| 248 |
P190 - The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF 04965842, A JAK1 inhibitor in clinical development
|
Dowty, Martin
|
|
|
35 |
1S |
p. S80
|
artikel
|
| 249 |
P81 - The impact of metabolite detection on adherence and the prevalence of drug-drug interactions in the behavioral health population through urine toxicology testing
|
Saucier, Leigh Ann
|
|
|
35 |
1S |
p. S46-S47
|
artikel
|
| 250 |
P83 - The natural product kratom is a potential precipitant of pharmacokinetic interactions with common drugs of abuse
|
Tanna, Rakshit
|
|
|
35 |
1S |
p. S47
|
artikel
|
| 251 |
P153 - The natural product 2-methoxy trans-cinnamaldehyde is a time dependent inhibitor of the nicotine and letrozole metabolizing enzyme cytochrome P450 2A6
|
Espiritu, Michael
|
|
|
35 |
1S |
p. S69
|
artikel
|
| 252 |
P110 - The phenotyping of solute carrier transporters in human primary hepatocytes: A chemical inhibition approach
|
Bi, Yi-an
|
|
|
35 |
1S |
p. S55-S56
|
artikel
|
| 253 |
P101 - The role of L- and D-menthol in the glucuronidation and detoxification of the major lung carcinogen, NNK
|
Kozlovich, Shannon
|
|
|
35 |
1S |
p. S53
|
artikel
|
| 254 |
P166 - The sudoxicam family: Identifying how thiazole structure determines bioactivation relevance
|
Barnette, Dustyne
|
|
|
35 |
1S |
p. S73
|
artikel
|
| 255 |
P35 - The use of primary cryopreserved human hepatocytes as a model for non-alcoholic fatty liver disease (NAFLD) related changes in phase I and phase II enzyme activities
|
Cottier, Karissa
|
|
|
35 |
1S |
p. S31-S32
|
artikel
|
| 256 |
P44 - Tissue distribution of EDP-305, a highly selective and potent farnesoid X receptor (FXR) agonist, in preclinical species
|
Huang, Meng
|
|
|
35 |
1S |
p. S34
|
artikel
|
| 257 |
P93 - Tissue stem cell derived human intestinal organoids: A novel and physiologically relevant model to evaluate cytochrome P450 induction in gut
|
Stresser, David
|
|
|
35 |
1S |
p. S50
|
artikel
|
| 258 |
P116 - Toxicity of hydrophobic and hydrophillic microcystin congeners on primary human hepatocytes
|
Richardson, Vicki
|
|
|
35 |
1S |
p. S57-S58
|
artikel
|
| 259 |
P49 - Uncovering novel lysosomal pH changes caused by dmDNA31, a novel rifalog payload of an antibody-antibiotic conjugate (AAC) in development to treat staphylococcus aureus infections
|
Vogt, Jennifer
|
|
|
35 |
1S |
p. S36
|
artikel
|
| 260 |
P46 - Understanding the excretion profile and the metabolism of pitolisant in CYP450 2D6 poor and extensive metabolisers at steady state
|
Shaw, Iain
|
|
|
35 |
1S |
p. S35
|
artikel
|
| 261 |
P221 - Understanding the pharmacokinetic nonlinearity of tabalumab by incorporating target-mediated drug disposition in a physiologically-based pharmacokinetic model
|
Zhou, Lian
|
|
|
35 |
1S |
p. S89-S90
|
artikel
|
| 262 |
P175 - Urinary estrogen derivatization and high-resolution LC-MS analysis to determine modulation of estrogen metabolism in women resulting from use of botanical dietary supplements
|
Wong, Alan
|
|
|
35 |
1S |
p. S76
|
artikel
|
| 263 |
P234 - Use of a bile salt export pump knockdown rat susceptibility model to interrogate mechanism of drug induced liver toxicity
|
Li, Yutai
|
|
|
35 |
1S |
p. S93
|
artikel
|
| 264 |
P10 - Use of microbial biotransformation to produce scalable quantities of a glucuronidated metabolite of the clinical-stage soluble guanylate cyclase inhibitor praliciguat
|
Shanu-Wilson, Julia
|
|
|
35 |
1S |
p. S25
|
artikel
|
| 265 |
P5 - Use of the HμREL® human hepatocyte co-culture model to determine intrinsic clearance and elucidate metabolic pathways of stable compounds
|
Butler, Philip
|
|
|
35 |
1S |
p. S24
|
artikel
|
| 266 |
P58 - Utilising a dual human transporter MDCK_MDR1_BCRP cell line to assess efflux at the blood brain barrier
|
McGinnity, Dermot
|
|
|
35 |
1S |
p. S39
|
artikel
|
| 267 |
P250 - Utility of ion mobility-enabled high resolution mass spectrometry and CCS prediction for characterizing isomeric metabolites in biotransformation studies
|
Clayton, Richard
|
|
|
35 |
1S |
p. S98
|
artikel
|
| 268 |
P7 - Utilization of a microphysiological system to model renal secretion of opioids in humans
|
Imaoka, Tomoki
|
|
|
35 |
1S |
p. S24
|
artikel
|
| 269 |
P103 - Validation of UGT inhibition assays for DDI assessment
|
Webber, Guy
|
|
|
35 |
1S |
p. S53
|
artikel
|
| 270 |
P237 - Variability of OATP1B1/1B3 in vitro inhibition constants and the resulting impact on clinical evaluation
|
McFeely, Savannah
|
|
|
35 |
1S |
p. S94
|
artikel
|
| 271 |
P15 - Vitamin D deficiency alters CYP3A gene expression and pharmacokinetics of dexamethasone
|
Annu, Kavya
|
|
|
35 |
1S |
p. S26
|
artikel
|
| 272 |
S4.2 - Activity-based profiling of the microbiome response to chemical exposures
|
Wright, Aaron
|
|
|
35 |
1S |
p. S9
|
artikel
|
| 273 |
S9.1 - Albumin-mediated hepatic uptake of organic anion transport polypeptide substrates
|
Sugiyama, Yuichi
|
|
|
35 |
1S |
p. S14-S15
|
artikel
|
| 274 |
S6.3 - Application of in silico DMPK in drug discovery and development
|
Broccatelli, Fabio
|
|
|
35 |
1S |
p. S12
|
artikel
|
| 275 |
S2.4 - Biofabrication of liver constructs for drug toxicity studies
|
Schneeberger, Kerstin
|
|
|
35 |
1S |
p. S8
|
artikel
|
| 276 |
S8.1 - Biomarkers for in vivo assessment of transporter function
|
Fromm, Martin F.
|
|
|
35 |
1S |
p. S13
|
artikel
|
| 277 |
S6.4 - Biosynthesis of drug candidates and metabolites
|
Griffith (Griff) Humphreys, W.
|
|
|
35 |
1S |
p. S12
|
artikel
|
| 278 |
S10.4 - Building, verifying and validating pediatric PBPK models: Vulnerabilities and knowledge deficits
|
Zhao, Ping
|
|
|
35 |
1S |
p. S16
|
artikel
|
| 279 |
SC1.2 - Advancing predictions of tissue and intracellular drug concentrations using in vitro and PBPK modeling approaches
|
Guo, Yingying
|
|
|
35 |
1S |
p. S1
|
artikel
|
| 280 |
SC2.1 - An overview of non-P450-mediated metabolism in drug development
|
Khojasteh, Cyrus
|
|
|
35 |
1S |
p. S2
|
artikel
|
| 281 |
SC3.2 - Application of QSP in drug discovery
|
Thompson, R. Adam
|
|
|
35 |
1S |
p. S3
|
artikel
|
| 282 |
SC1.5 - A Regulatory perspective "Transporters in drug development: Scientific and regulatory considerations"
|
Zhang, Lei K.
|
|
|
35 |
1S |
p. S2
|
artikel
|
| 283 |
SC1.4 - Can BSEP inhibition testing in drug discovery and development reduce liver injury risk? An international transporter consortium perspective
|
Kenna, Gerry
|
|
|
35 |
1S |
p. S1-S2
|
artikel
|
| 284 |
SC4.3 - Cellular and animal models of idiosyncratic drug-induced liver injury
|
Yokoi, Tsuyoshi
|
|
|
35 |
1S |
p. S4-S5
|
artikel
|
| 285 |
SC4.2 - Clinical aspects of hepatocellular and cholestatic drug-induced liver injury
|
Björnsson, Einar S.
|
|
|
35 |
1S |
p. S4
|
artikel
|
| 286 |
SC2.3 - Enzymology and clinical importance of reductases and hydrolases
|
Cerny, Matthew A.
|
|
|
35 |
1S |
p. S2
|
artikel
|
| 287 |
SC1.3 - Influence of transporter polymorphisms on drug disposition and response: A Perspective from the international transporter consortium
|
Yee, Sook Wah
|
|
|
35 |
1S |
p. S1
|
artikel
|
| 288 |
SC3.1 - Introduction to QSP
|
van der Graaf, Piet
|
|
|
35 |
1S |
p. S3
|
artikel
|
| 289 |
S1.3 - CPIC guidelines and implementation to date
|
Caudle, Kelly
|
|
|
35 |
1S |
p. S6-S7
|
artikel
|
| 290 |
SC4.4 - Progress made in understanding genetically-inherited susceptibility factors, including hla genotype
|
Daly, Ann K.
|
|
|
35 |
1S |
p. S5
|
artikel
|
| 291 |
SC2.2 - Role of glucuronidation in drug metabolism and toxicity
|
Fujiwara, Ryoichi
|
|
|
35 |
1S |
p. S2
|
artikel
|
| 292 |
SC1.1 - The next frontier in adme research: Predicting and verifying tissue drug concentrations using a proteomics and pet imaging approach
|
Unadkat, Jashvant D.
|
|
|
35 |
1S |
p. S1
|
artikel
|
| 293 |
SC3.3 - Therapeutic area case study: QSP in immuno-oncology
|
Bihorel, Shihem
|
|
|
35 |
1S |
p. S3
|
artikel
|
| 294 |
SC3.4 - Therapeutic area case study: QSP in inflammatory disease
|
Gadkar, Kapil
|
|
|
35 |
1S |
p. S3-S4
|
artikel
|
| 295 |
SC4.1 - The role of inflammatory mediators in idiosyncratic drug-induced liver injury
|
Uetrecht, Jack
|
|
|
35 |
1S |
p. S4
|
artikel
|
| 296 |
SC2.4 - Toxicological relevance of non-P450 enzymes: Hydrolases and aldehyde oxidase
|
Fukami, Tatsuki
|
|
|
35 |
1S |
p. S3
|
artikel
|
| 297 |
SC3.5 - Tutorial: How to build a QSP model in less than one hour
|
Kierzek, Andrzej
|
|
|
35 |
1S |
p. S4
|
artikel
|
| 298 |
S4.4 - Developmental reprogramming of the gut microbiota by environmental toxicants
|
Cui, Julia Yue
|
|
|
35 |
1S |
p. S9-S10
|
artikel
|
| 299 |
S3.1 - Development and application of a PBPK model for large molecules in Pfizer
|
Jones, Hannah
|
|
|
35 |
1S |
p. S8
|
artikel
|
| 300 |
S9.2 - Effects of albumin on prediction of liver KPUU and human hepatic clearance for enzyme- and transporter-mediated mechanisms
|
Di, Li
|
|
|
35 |
1S |
p. S15
|
artikel
|
| 301 |
S11.2 - Elagolix: A mechanistic understanding of drug-drug interactions
|
Stresser, David
|
|
|
35 |
1S |
p. S16
|
artikel
|
| 302 |
S7.3 - Enabling Asia-inclusive global drug development through quantitative and translational science
|
Venkatakrishnan, Karthik
|
|
|
35 |
1S |
p. S13
|
artikel
|
| 303 |
S9.3 - Impact of albumin and plasma on the renal uptake of OAT1 substrates
|
Masereeuw, Rosalinde (Roos)
|
|
|
35 |
1S |
p. S15
|
artikel
|
| 304 |
S4.1 - Impact of intestinal flora on host metabolism of drug, sugar and lipid
|
Ohtsuki, Sumio
|
|
|
35 |
1S |
p. S9
|
artikel
|
| 305 |
S7.4 - Impact of Racial/Ethnic differences in drug response: Regulatory perspectives
|
Ramamoorthy, Anuradha
|
|
|
35 |
1S |
p. S13
|
artikel
|
| 306 |
S4.3 - Impact of the human gut microbiome on drug disposition
|
Turnbaugh, Peter
|
|
|
35 |
1S |
p. S9
|
artikel
|
| 307 |
S8.4 - Integrated quantitative proteomics and metabolomics approach for discovery and validation of UGT2B17 biomarker to predict drug metabolism
|
Prasad, Bhagwat
|
|
|
35 |
1S |
p. S14
|
artikel
|
| 308 |
S2.2 - Kidney organoids for disease modeling and high throughput screening
|
Freedman, Benjamin
|
|
|
35 |
1S |
p. S7
|
artikel
|
| 309 |
S8.3 - Knockout mice, transcriptomics and metabolomics approach for discovery of endogenous biomarkers for renal drug transporters
|
Nigam, Sanjay
|
|
|
35 |
1S |
p. S14
|
artikel
|
| 310 |
S5.4 - Liver transporter activity in patients with renal disease
|
Stoch, Aubrey
|
|
|
35 |
1S |
p. S11
|
artikel
|
| 311 |
S11.4 - Management of mist in a case of multiple metabolic species differences
|
Weidolf, Lars
|
|
|
35 |
1S |
p. S17
|
artikel
|
| 312 |
S8.2 - Mechanistic models for coproporphyrin I and creatinine as endogenous biomarkers for transporter drug-drug interactions
|
Galetin, Aleksandra
|
|
|
35 |
1S |
p. S13
|
artikel
|
| 313 |
S11.1 - Navigating through discovery and development painlessly: Snapshots within the NAV1.7 Program
|
Chang, Jae
|
|
|
35 |
1S |
p. S16
|
artikel
|
| 314 |
S10.1 - Ontogeny of human membrane transporters: From data to application
|
de Wildt, Saskia
|
|
|
35 |
1S |
p. S15
|
artikel
|
| 315 |
S3.2 - PBPK and PKPD modeling to investigate engineered antibodies
|
Tachibana, Tatsuhiko
|
|
|
35 |
1S |
p. S8
|
artikel
|
| 316 |
S3.3 - PBPK models for predicting human PK for monoclonal antibodies and other large molecule modalities
|
Gardner, Iain
|
|
|
35 |
1S |
p. S8
|
artikel
|
| 317 |
S10.2 - Pediatric PBPK: Dealing with uncertain parameters and deciding on success criteria for predictability
|
Johnson, Trevor
|
|
|
35 |
1S |
p. S15-S16
|
artikel
|
| 318 |
S1.4 - Personalised treatment of cancer
|
McLeod, Howard
|
|
|
35 |
1S |
p. S7
|
artikel
|
| 319 |
S6.1 - Predicting routes, sites, and products of metabolism
|
Segall, Matthew
|
|
|
35 |
1S |
p. S11
|
artikel
|
| 320 |
S7.1 - Prediction of differences in pharmacokinetics between Chinese, Japanese, and Caucasian populations - an update
|
Tucker, Geoffrey
|
|
|
35 |
1S |
p. S12
|
artikel
|
| 321 |
S5.1 - Proteomics based studies of disease effects on the brain barrier transporters
|
Terasaki, Tetsuya
|
|
|
35 |
1S |
p. S10
|
artikel
|
| 322 |
S2.3 - Real-time toxicity assessment on perfused 3D epithelial tubes
|
Trietsch, Bas
|
|
|
35 |
1S |
p. S7-S8
|
artikel
|
| 323 |
S1.2 - Relevance of transporter and metabolic SNPS to pediatric treatment
|
Fukuda, Tsuyoshi
|
|
|
35 |
1S |
p. S6
|
artikel
|
| 324 |
S5.2 - SLC16A11: From human genetics to novel mechanisms underlying type 2 diabetes
|
Hoch, Eitan
|
|
|
35 |
1S |
p. S10
|
artikel
|
| 325 |
S6.2 - Substrate recognition by cytochrome P450s
|
Scott, Emily E.
|
|
|
35 |
1S |
p. S11-S12
|
artikel
|
| 326 |
S3.4 - Systems PK/PD model informed discovery and development of cancer immunotherapy
|
Shah, Dhaval
|
|
|
35 |
1S |
p. S9
|
artikel
|
| 327 |
S2.1 - "Tissues on Chips"- A novel tool for toxicity and efficacy testing on human tissue
|
Lee, Bo Yeon
|
|
|
35 |
1S |
p. S7
|
artikel
|
| 328 |
S7.2 - Transporter polymorphisms drive inter-ethnic differences in drug response
|
Giacomini, Kathy
|
|
|
35 |
1S |
p. S12
|
artikel
|
| 329 |
S5.3 - Transporters in polycystic kidney disease
|
Brouwer, Kim
|
|
|
35 |
1S |
p. S10-S11
|
artikel
|
| 330 |
S10.3 - Use of ‘Virtual Children’ to inform exposure-controlled dosing of drugs in children
|
Dinh, Jean C.
|
|
|
35 |
1S |
p. S16
|
artikel
|
| 331 |
S1.1 - Warfarin: A paradigm for individualized dosing
|
Pirmohamed, Munir
|
|
|
35 |
1S |
p. S6
|
artikel
|
| 332 |
S11.3 - Zepatier: The tale of two novels
|
Fandozzi, Christine
|
|
|
35 |
1S |
p. S16-S17
|
artikel
|
| 333 |
Title page
|
|
|
|
35 |
1S |
p. i
|
artikel
|
| 334 |
TOC
|
|
|
|
35 |
1S |
p. ii-iii
|
artikel
|
Tijdschrift beschrijving